Annovis Bio, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Annovis Bio, Inc. (ANVS) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.61 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-14
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $1.61M, a 223.92% increase year-over-year.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $182.82K, a 63.43% decline year-over-year.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $444.65K, a 13.12% increase year-over-year.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $496.62K, a 68.89% decline year-over-year.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $1.80M, a 53.15% decline from fiscal 2024.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $3.84M, a 17.10% decline from fiscal 2023.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $4.63M, a 49.43% decline from fiscal 2022.
- Annovis Bio, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $9.15M, a 94.83% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.61M 10-Q · filed 2026-08-14 | $1.79M derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $182.82K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $1.80M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $444.65K 10-Q · filed 2025-11-12 | $941.26K derived: sum of 2 quarters · filed 2026-08-14 | $1.44M derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $496.62K 10-Q · filed 2026-08-14 | $996.50K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $499.89K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $3.84M 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $393.08K 10-Q · filed 2025-11-12 | $1.99M derived: sum of 2 quarters · filed 2025-11-12 | $2.35M derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $1.60M 10-Q · filed 2025-11-12 | $1.96M derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $364.76K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $4.63M 10-K · filed 2025-03-21 | |||
| 2023-09-30 | $632.19K 10-Q · filed 2024-11-08 | $2.20M derived: sum of 2 quarters · filed 2024-11-08 | $3.75M derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $1.57M 10-Q · filed 2024-11-08 | $3.11M derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $1.54M 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $9.15M 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $2.36M 10-Q · filed 2023-11-08 | $4.26M derived: sum of 2 quarters · filed 2023-11-08 | $7.69M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-30 | $1.90M 10-Q · filed 2023-11-08 | $5.34M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-31 | $3.43M 10-Q · filed 2023-11-08 | |||
| 2021-12-31 | $4.70M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | $785.94K 10-Q · filed 2022-11-08 | $793.93K derived: sum of 2 quarters · filed 2022-11-08 | $817.91K derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $7.99K 10-Q · filed 2022-11-08 | $31.97K derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $23.98K 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $1.74M 10-K · filed 2022-03-02 | |||
| 2020-09-30 | $607.07K 10-Q · filed 2021-11-03 | $1.72M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-06-30 | $1.11M 10-Q · filed 2021-11-03 | |||
| 2019-12-31 | $8.48K 10-K · filed 2021-03-03 | |||
| 2019-03-31 | $8.86K 10-Q · filed 2020-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |